Clinical Trial Update: Pre-Exposure Prophylaxis Using TMC278LA [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study evaluating the long-acting rilpivirine formulation (TMC278LA) for HIV pre-exposure prophylaxis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC278LA (rilpivirine long-acting formulation)

Snippet

Sponsor: St Stephens Aids Trust | Conditions: HIV Infections | Phase 1, Phase 2 | Status: TERMINATED